TABLE 1.
Patient and tumor characteristics
| Item | Before propensity matching | After 1:2 propensity matching | ||||||
|---|---|---|---|---|---|---|---|---|
|
TTS ≤ 5 wk (n = 27) |
TTS > 5 wk (n = 74) | P | All patients (n = 101) | TTS ≤ 5 wk (n = 24) | TTS > 5 wk (n = 37) | P | All patients (n = 61) | |
| Age > 60 y, n (%) | 12 (44.4) | 26 (35.1) | .393 | 38 (37.6) | 11 (45.8) | 14 (37.8) | .535 | 25 (41.0) |
| Male, n (%) | 14 (51.9) | 49 (66.2) | .187 | 63 (62.4) | 12 (50.0) | 26 (70.3) | .111 | 38 (62.3) |
| BMI > 24 kg/m2, n (%) | 10 (37.7) | 43 (58.1) | .061 | 53 (52.5) | 9 (37.5) | 22 (59.5) | .194 | 31 (50.8) |
| ALB > 40 g/L, n (%) | 16 (59.3) | 51 (68.9) | .363 | 67 (66.3) | 13 (54.2) | 27 (73.0) | .131 | 40 (65.6) |
| High CONUT score, n (%) | 7 (25.9) | 20 (27.0) | .912 | 27 (26.7) | 7 (29.2) | 13 (35.1) | .628 | 20 (32.8) |
| Comorbidity, n (%) | 10 (37.0) | 38 (51.4) | .202 | 48 (47.5) | 8 (33.3) | 19 (51.4) | .166 | 27 (44.3) |
| ASA score 3‐4, n (%) | 2 (7.4) | 9 (12.2) | .497 | 11 (10.9) | 3 (8.1) | 2 (8.3) | .975 | 5 (8.2) |
| Preoperative CEA > 10 ng/mL, n (%) | 12 (44.4) | 34 (45.9) | .893 | 46 (45.5) | 11 (45.8) | 18 (48.6) | .830 | 29 (47.5) |
| Synchronous metastasis, n (%) | 21 (77.8) | 67 (90.5) | .090 | 88 (87.1) | 21 (87.5) | 31 (83.8) | .689 | 52 (85.2) |
| Left hemicolon, n (%) | 4 (14.8) | 8 (10.8) | .582 | 12 (11.9) | 3 (12.5) | 4 (10.8) | .840 | 7 (11.5) |
| R0 resection, n (%) | 14 (51.9) | 45 (60.8) | .419 | 59 (58.4) | 13 (54.2) | 26 (70.3) | .201 | 39 (63.9) |
| Major liver resection, n (%) | 16 (59.3) | 49 (66.2) | .518 | 65 (64.4) | 13 (54.2) | 25 (67.6) | .291 | 38 (62.3) |
| Heterochronous resection, n (%) | 6 (22.2) | 17 (23.0) | .937 | 23 (22.8) | 5 (20.8) | 10 (27.0) | .583 | 15 (24.6) |
| Bilobar distribution, n (%) | 11 (40.7) | 42 (56.8) | .154 | 53 (52.5) | 9 (37.5) | 20 (54.1) | .206 | 29 (47.5) |
| Extrahepatic metastases, n (%) | 4 (14.8) | 8 (10.8) | .582 | 12 (11.9) | 3 (12.5) | 4 (10.8) | .840 | 7 (11.5) |
| Diameter of metastases >3 cm, n (%) | 13 (48.1) | 34 (45.9) | .844 | 47 (46.5) | 11 (45.8) | 14 (37.8) | .535 | 25 (41.0) |
| Multiple metastases, n (%) | 17 (63.0) | 57 (77.0) | .158 | 74 (73.3) | 15 (62.5) | 26 (70.3) | .528 | 41 (67.2) |
| Poor differentiation, n (%) | 5 (18.5) | 25 (33.8) | .137 | 30 (29.1) | 5 (20.8) | 12 (32.4) | .324 | 17 (27.9) |
| pT3‐T4, n (%) | 21 (77.8) | 68 (91.9) | .052 | 89 (88.1) | 18 (75.0) | 32 (86.5) | .254 | 50 (82.0) |
| Node‐positive primary tumor, n (%) | 19 (70.4) | 51 (68.9) | .889 | 70 (69.3) | 17 (70.8) | 22 (59.5) | .366 | 39 (63.9) |
| pN1 stage, n (%) | 9 (33.3) | 39 (52.7) | .085 | 48 (47.5) | 8 (33.3) | 15 (40.5) | .570 | 23 (37.7) |
| pN2 stage, n (%) | 10 (37.0) | 12 (16.2) | .025 | 22 (21.8) | 9 (37.5) | 7 (18.9) | .107 | 16 (26.2) |
| NAC toxicity, n (%) | 24 (88.9) | 60 (81.1) | .353 | 84 (83.2) | 21 (87.5) | 29 (78.4) | .365 | 50 (82.0) |
| Neutropenia, n (%) | 13 (48.1) | 30 (40.5) | .494 | 43 (42.6) | 11 (45.8) | 16 (43.2) | .842 | 27 (44.3) |
| KRAS mutation, n (%) a | 4 (14.8) | 11 (14.9) | .679 | 15 (14.9) | 3 (23.1) | 3 (13.6) | .474 | 6 (17.1) |
| Preoperative chemotherapy | ||||||||
| Oxaliplatin‐based regimen, n (%) | 24 (88.9) | 64 (86.5) | .750 | 88 (87.1) | 22 (91.7) | 32 (86.5) | .535 | 54 (88.5) |
| Cycles > 7, n (%) | 2 (7.4) | 22 (29.7) | .020 | 24 (23.8) | 2 (8.3) | 6 (16.2) | .373 | 8 (13.1) |
| Targeted therapy, n (%) | 11 (40.7) | 28 (37.8) | .791 | 39 (38.6) | 9 (37.5) | 15 (40.5) | .812 | 24 (39.3) |
| Pathological response, n (%) | 14 (51.9) | 18 (24.3) | .008 | 32 (31.7) | 12 (50.0) | 15 (40.5) | .467 | 27 (44.3) |
| Clinical response, n(%) | 15 (55.6) | 33 (44.6) | .329 | 48 (47.5) | 14 (58.3) | 21 (56.8) | .903 | 35 (57.4) |
| Complications, n (%) | 15 (55.6) | 44 (59.5) | .725 | 59 (58.4) | 13 (54.2) | 21 (56.8) | .842 | 34 (55.7) |
| Minor complications, n (%) | 10 (37.0) | 24 (32.4) | .665 | 34 (33.7) | 8 (33.3) | 12 (32.4) | .942 | 20 (32.8) |
| Major complications, n (%) | 5 (18.5) | 20 (27.0) | .381 | 25 (24.8) | 5 (20.8) | 9 (24.3) | .751 | 14 (23.0) |
| Postoperative chemotherapy, n (%) | 18 (66.7) | 40 (54.1) | .257 | 58 (57.4) | 17 (70.8) | 20 (54.1) | .190 | 37 (60.7) |
Abbreviations: BMI, body mass index; NAC, neoadjuvant chemotherapy; TTS, time to surgery.
a
KRAS status was available in 66 patients before propensity matching and in 35 patients after propensity matching.